Log in

NASDAQ:ALDXAldeyra Therapeutics Stock Price, Forecast & News

+0.03 (+0.71 %)
(As of 05/25/2020 11:10 AM ET)
Today's Range
Now: $4.27
50-Day Range
MA: $2.93
52-Week Range
Now: $4.27
Volume675,341 shs
Average Volume1.02 million shs
Market Capitalization$127.20 million
P/E RatioN/A
Dividend YieldN/A
Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. Aldeyra Therapeutics, Inc. has a collaborative research agreement with Janssen Research & Development, LLC for the development of novel immune-modulating drugs for systemic inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.
Read More
Aldeyra Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.04 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ALDX



Sales & Book Value

Annual SalesN/A
Book Value$1.72 per share


Net Income$-60,830,000.00


Market Cap$127.20 million
Next Earnings Date8/13/2020 (Estimated)

Receive ALDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.

Aldeyra Therapeutics (NASDAQ:ALDX) Frequently Asked Questions

How has Aldeyra Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Aldeyra Therapeutics' stock was trading at $2.79 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ALDX stock has increased by 53.0% and is now trading at $4.27. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aldeyra Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aldeyra Therapeutics.

When is Aldeyra Therapeutics' next earnings date?

Aldeyra Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Aldeyra Therapeutics.

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) posted its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.14. View Aldeyra Therapeutics' earnings history.

What price target have analysts set for ALDX?

2 brokerages have issued 12-month price targets for Aldeyra Therapeutics' shares. Their forecasts range from $12.00 to $33.00. On average, they expect Aldeyra Therapeutics' stock price to reach $22.50 in the next twelve months. This suggests a possible upside of 426.9% from the stock's current price. View analysts' price targets for Aldeyra Therapeutics.

Has Aldeyra Therapeutics been receiving favorable news coverage?

Headlines about ALDX stock have been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aldeyra Therapeutics earned a coverage optimism score of 1.5 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutAldeyra Therapeutics.

Are investors shorting Aldeyra Therapeutics?

Aldeyra Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 483,600 shares, an increase of 18.3% from the April 30th total of 408,900 shares. Based on an average daily volume of 282,700 shares, the days-to-cover ratio is currently 1.7 days. Approximately 1.8% of the shares of the stock are sold short. View Aldeyra Therapeutics' Current Options Chain.

Who are some of Aldeyra Therapeutics' key competitors?

What other stocks do shareholders of Aldeyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include Amarin (AMRN), Inovio Pharmaceuticals (INO), Micron Technology (MU), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Sangamo Therapeutics (SGMO), TherapeuticsMD (TXMD), Amicus Therapeutics (FOLD) and Abeona Therapeutics (ABEO).

Who are Aldeyra Therapeutics' key executives?

Aldeyra Therapeutics' management team includes the following people:
  • Dr. Todd C. Brady, Chief Exec. Officer, Pres and Director (Age 46)
  • Mr. Stephen J. Tulipano CPA, MBA, Chief Financial Officer and Treasurer (Age 59)
  • Dr. David J. Clark M.D., M.R.C.P., A.F.P.M., Chief Medical Officer (Age 53)
  • Ms. Mary Taylor M.P.H., Sr. VP of Regulatory Affairs (Age 59)

What is Aldeyra Therapeutics' stock symbol?

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

Who are Aldeyra Therapeutics' major shareholders?

Aldeyra Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Prosight Management LP (6.83%), BlackRock Inc. (5.44%), State Street Corp (1.35%), Geode Capital Management LLC (1.12%), Weiss Multi Strategy Advisers LLC (0.49%) and Private Advisors LLC (0.46%). Company insiders that own Aldeyra Therapeutics stock include Ben Bronstein, David Mcmullin, Jesse I Treu, Joshua Reed, Richard Douglas and Todd C Brady. View institutional ownership trends for Aldeyra Therapeutics.

Which institutional investors are selling Aldeyra Therapeutics stock?

ALDX stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Weiss Multi Strategy Advisers LLC, UBS Group AG, Hikari Power Ltd, Deutsche Bank AG, State Street Corp, Parametric Portfolio Associates LLC, and Bank of New York Mellon Corp. View insider buying and selling activity for Aldeyra Therapeutics.

Which institutional investors are buying Aldeyra Therapeutics stock?

ALDX stock was bought by a variety of institutional investors in the last quarter, including Prosight Management LP, Two Sigma Investments LP, JPMorgan Chase & Co., Private Advisors LLC, Tobias Financial Advisors Inc., Squarepoint Ops LLC, BlackRock Inc., and Acadian Asset Management LLC. Company insiders that have bought Aldeyra Therapeutics stock in the last two years include Ben Bronstein, David Mcmullin, Joshua Reed, Richard Douglas, and Todd C Brady. View insider buying and selling activity for Aldeyra Therapeutics.

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aldeyra Therapeutics' stock price today?

One share of ALDX stock can currently be purchased for approximately $4.27.

How big of a company is Aldeyra Therapeutics?

Aldeyra Therapeutics has a market capitalization of $127.20 million. The biotechnology company earns $-60,830,000.00 in net income (profit) each year or ($2.05) on an earnings per share basis.

What is Aldeyra Therapeutics' official website?

The official website for Aldeyra Therapeutics is www.ampliphibio.com.

How can I contact Aldeyra Therapeutics?

Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-761-4904 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.